IMPAACT 2036

IMPAACT 2036 is a Phase I/II, multi-center, open-label, non-comparative pharmacokinetic (PK) and safety study of cabotegravir (CAB) and rilpivirine (RPV) when taken orally (oral CAB + oral RPV) followed by long-acting injections (CAB LA + RPV LA) in virologically suppressed children living with HIV, aged 2 to less than 12 years of age and weighing 10kg to 50kg. The study is designed to determine the weight band dosing regimen and evaluate the safety, tolerability, PK, and antiviral activity of oral CAB + oral RPV followed by CAB LA + RPV LA. Two sequential cohorts will be enrolled and participants will be followed for 24 weeks (Cohort 1) and 72 weeks (Cohort 2) of study treatment.